The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer.

Autor: Hannarici Z; Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey., Yılmaz A; Department of Medical Oncology, Health Sciences University Mehmet Akif İnan Training & Research Hospital, Şanlıurfa, 63040, Turkey., Buyukbayram ME; Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey., Turhan A; Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey., Çağlar AA; Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey., Bilici M; Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey., Tekin SB; Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, 25100, Turkey.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2023 Feb; Vol. 19 (4), pp. 315-325. Date of Electronic Publication: 2023 Mar 09.
DOI: 10.2217/fon-2022-0579
Abstrakt: Aim: To demonstrate the prognostic importance of glucose-to-lymphocyte ratio (GLR) in metastatic gastric cancer (mGC). Methods: Retrospectively, 159 mGC patients were enrolled. Kaplan-Meier curve and Cox regression analysis were used to determine the prognostic value of the systemic immune inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), prognostic nutritional index (PNI) and GLR. Results: Progression-free survival (PFS) and overall survival (OS) were associated with NLR, PNI, SII and GLR by univariate analysis. Moreover, OS was associated with Eastern Cooperative Oncology Group performance status and the chemotherapy regimen. In multivariate analysis, only GLR was found to be independently prognostic for both PFS and OS. Conclusion: In mGC, GLR may be a new prognostic marker for both OS and PFS.
Databáze: MEDLINE